Disease Overview：Fibrillary glomerulopathy（FG）
Fibrillary glomerulopathy is a rare, progressive immune-mediated kidney disorder characterized by the deposition of non-amyloid, randomly oriented fibrils (10–20 nm in diameter) within the glomerular basement membrane and mesangium. It predominantly affects adults aged 50–70 years and typically presents with nephrotic-range proteinuria, microscopic hematuria, hypertension, and gradual decline in estimated glomerular filtration rate (eGFR). Diagnosis requires renal biopsy with electron microscopy confirmation—distinguishing it from immunotactoid glomerulopathy and amyloidosis—and often includes immunofluorescence showing polyclonal IgG and complement C3 deposits. No universally effective therapy exists; management focuses on renin-angiotensin system blockade, immunosuppression (e.g., corticosteroids, cyclophosphamide, or rituximab), and supportive care. Prognosis varies: approximately 40–60% progress to end-stage kidney disease within 5–10 years without intervention.
China offers distinct advantages for international patients seeking care: leading nephrology centers—such as Peking University First Hospital and Shanghai Renji Hospital—boast internationally trained specialists with extensive experience in rare glomerulopathies, advanced diagnostic platforms including high-resolution electron microscopy and mass spectrometry-based proteomics, and access to novel biologics and clinical trials. Published outcomes demonstrate improved remission rates and delayed dialysis initiation compared to historical cohorts. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality or regulatory compliance. As a dedicated medical tourism agency, we facilitate seamless access—handling hospital referrals, coordinating biopsy interpretation by certified renal pathologists, clarifying all-inclusive pricing upfront, and providing end-to-end support from visa assistance to post-discharge follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Fibrillary Glomerulopathy (Nephrology)
Non-Surgical / Conservative / Medication-Based Management
*Target Criteria:* Early-stage disease (eGFR ≥60 mL/min/1.73m²), minimal proteinuria (<1 g/day), stable renal function, no active systemic inflammation.
- •Immunosuppressive Therapy (First-Line)
- *Prednisone (0.5 mg/kg/day ×4 wks, taper)*: $45–$65 - *Cyclophosphamide (oral, 1.5–2 mg/kg/day ×3–6 mos)*: $180–$220
- •Supportive Care
- Statin (atorvastatin 20 mg/day): $35–$50
- •Monitoring Labs & Exams (per 3-month cycle)
- 24-hr urine protein + creatinine clearance: $85 - Renal ultrasound (Doppler): $145
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Rapidly progressive GN (eGFR decline >5 mL/min/yr), nephrotic-range proteinuria (>3.5 g/day), biopsy-confirmed active fibrillary deposits with crescents or interstitial fibrosis.
- •Therapeutic Plasma Exchange (TPE)
- *Pre-op workup (coagulation panel, PT/INR, hepatitis serology, vascular access assessment)*: $290
- •Kidney Biopsy (Repeat for treatment response assessment)
- *Electron microscopy + immunofluorescence add-on*: $460
Special / Complex Condition Management
- •End-Stage Renal Disease (ESRD) Transition
- *Peritoneal dialysis catheter placement + training*: $2,100–$2,550
- •Refractory Disease (Failure of rituximab + steroids)
- *Bone marrow evaluation (for occult lymphoma screening)*: $1,320
Quick Selection Guide
- •Young adult (<45 y), mild proteinuria, budget-conscious: Start with ACEi/ARB + low-dose prednisone ($140–$200 initial 3-mo cost) — avoids high-cost biologics unless progression occurs.
- •Middle-aged (45–65 y), rapid eGFR decline, moderate comorbidities (HTN, DM): Rituximab + TPE ($7,050–$8,500 upfront) — balances efficacy and renal preservation.
- •Elderly (>65 y), ESRD or frailty, limited life expectancy: Supportive care + timely dialysis transition ($2,100–$2,550 for PD setup) — prioritizes quality of life over aggressive immunosuppression.
- •Refractory cases with monoclonal gammopathy: Bortezomib + hematologic workup ($8,120 total) — mandatory if serum free light chains abnormal or bone marrow shows clonal plasma cells.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Fibrillary glomerulopathy Medical Vacation Packages
Curated transparent all-inclusive packages combining Fibrillary glomerulopathy treatment with China top medical destinations:
